Granulomatous hepatitis, not elsewhere classified
ICD-10 K75.3 is a billable code used to indicate a diagnosis of granulomatous hepatitis, not elsewhere classified.
Granulomatous hepatitis is a rare form of liver inflammation characterized by the presence of granulomas, which are small clusters of immune cells that form in response to chronic inflammation. Clinically, patients may present with nonspecific symptoms such as fatigue, malaise, jaundice, and abdominal discomfort. The liver, primarily involved in this condition, may show signs of hepatomegaly upon physical examination. The disease progression can vary; some patients may experience a self-limiting course, while others may develop chronic liver disease or cirrhosis if the underlying cause is not addressed. Diagnostic considerations include liver function tests, imaging studies such as ultrasound or CT scans, and liver biopsy, which is crucial for confirming the diagnosis by revealing granulomatous inflammation. Common etiologies include infections (e.g., tuberculosis, viral hepatitis), autoimmune diseases, and certain medications. Identifying the underlying cause is essential for effective management and treatment planning.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
K75.3 encompasses granulomatous hepatitis not classified elsewhere, including cases related to infections (like tuberculosis), autoimmune disorders (such as primary biliary cholangitis), and drug-induced liver injury. It is essential to identify the underlying cause for appropriate management.
K75.3 should be used when granulomatous hepatitis is diagnosed without a specific classification under other codes. It is important to differentiate it from other hepatitis types by confirming the presence of granulomas through biopsy and ruling out other causes.
Documentation should include clinical findings, laboratory results, imaging studies, and biopsy reports confirming granulomatous inflammation. A thorough history of potential exposures, medications, and associated conditions is also critical.
